|
|
|||||
|
Conflict of Interest / Disclosure Policy Whenever there is the potential for conflict of interest, details of funding, sponsorship, financial involvement and possible conflicts of interest will be prominently and fully disclosed. Specific Disclosures for 2008: Sponsorship for interviews this year at SCAI-ACC 2008 was provided by the Center for Health Education (CHE) through unrestricted education grants from Scios, Astellas and Daiichi/Lilly. Specific Disclosures for 2007: Sponsorship for interviews this year at AHA 2007 and TCT 2007 was provided by the Center for Health Education (CHE) through unrestricted education grants from Daiichi Sankyo Lilly, Genentech, Pfizer, Sanofi-Aventis, Schering-Plough and Scios. Sponsorship for the booth and interviews at ACC 2007 was provided by the Center for Health Education (CHE) through unrestricted education grants from the Medicines Company, Merck, Schering-Plough and Scios. Sponsorship for interviews at AHA 2006 was provided by the Center for Health Education (CHE) through an unrestricted education grant from Galaxo Smith Klein. General Disclosures: Dr. C. Michael Gibson, M.S., M.D., Editor-In-Chief Currently there is no direct funding for the development and maintenance of this webpage. Some CME programs are sponsored as indicated. We are currently seeking assistance from any interested parties. The site is supported by volunteer efforts from Susan J. Marble and Dr. C. Michael Gibson. Dr. Gibson is founder and director of PERFUSE (Percutaneous/Pharmacologic Endoluminal Revascularization For Unstable Syndromes & its Evaluation) and the TIMI Angiographic Core Laboraotories (non- profit entities) with over a decade of experience in cardiovascular research. Over the years PERFUSE / TIMI has received the research grant support from the following entities: Government Agencies The NIH (HARP, PEARL); HCFA (Medicare CABG project) Industry (in alphabetical order) Acusphere; Astra (STEP AMI); Aventis / RPR (TIMI 11, ENTIRE); Bard (Perfusion balloon trial); Boston Scientific (Wallgraft studies); Bristol Meyer Squibb (HARP, CLARITY); British Biotech; Ciba Geigy (TIMI 9); Millenium Pharmaceuticals / COR Therapeutics (ESPRIT / TITAN / ADVANCE MI / PROTECT); Corgentech (PREVENT 4); DVI Guidant (Intermediate vessel atherectomy trial); Eli Lilly / Centocor (TIMI 14, SPEED); Genentech (TIMI 10, TIMI 12, LIMIT, VIVA); Merck (RESTORE, TACTICS, TARGET); Park Davis (AVERT); Percusurge, Point Biomedical; Smith Kline Beecham (TIMI 4); Sonus (Echogen trial); St Judes (Evaluation of Proximal Anastomotic Device); The Medicines Company (research support and consultancy); TIMI 3 Systems (the PLUS trial).
The TIMI Study Group has received funding
from the following entities (in alphabetical order):
Accumetrics,
Inc.
Amgen, Inc.
AstraZeneca
Pharmaceuticals LP
Baxter
Bayer Healthcare
LLC
Beckman Coulter,
Inc.
Biosite
Incorporated
Bristol-Myers
Squibb
CardioKinetix
CV Therapeutics,
Inc.
Eli Lilly and
Company
FoldRx
GlaxoSmithKline
INO Therapeutics
LLC
Inotek
Pharmaceuticals Corporation
Integrated
Therapeutics Corporation
KAI
Pharmaceuticals
Merck &
Co., Inc.
Millennium Pharmaceuticals, Inc.
Novartis
Pharmaceuticals
Nuvelo,
Inc.
Ortho-Clinical Diagnostics, Inc.
Pfizer,
Inc.
Roche
Diagnostics Corporation
Roche
Diagnostics GmbH
Sanofi-Aventis
Sanofi-Synthelabo
Recherche
Schering-Plough Research Institute
St Jude
Medical
The
National Institutes of Health
Dr.
Gibson has received Research/Grant Support from the
following in the past (includes funding beyond one year
in the past) ActivBiotics Acusphere Astra Sanofi-Aventis Bard British Biotech Ciba Geigy Corgentech COR Therapeutics DVI Guidant Eli Lilly Genentech
Merck
Millennium Pharmaceuticals
NIH
Nuvelo
Pfizer
Percusurge Point Biomedical Smith Kline Beecham Sonus
timi3 Systems
Dr. Gibson's Present Research/Grant Funding
Archimex CardioKinetix Schering Plough Corporation Sanofi-Aventis Baxter Novartis FoldRx
INO
Therapeutics, LLC
Dr. Gibson on Following Speakers Bureau Eli Lilly Sanofii Aventis Schering Plough Corporation The Medicines Company
Dr. Gibson has Served
as a Consultant Angel Medical Systems The Medicines Company Ascenta Therapeutics, Inc. Archemix Corp. Heartscape Technologies PDL Pharmaceuticals Atrium Medical Corporation Timi3 Systems Biogen IDEC This website is owned and managed by PIXCELLA LLC. Contact the managing editor: smarble@clinicaltrialresults.org . Employees paid by Pixcella LLC for their time in filming, video-editing, managing the website: Erin Lord Scott Williams Lauren Ciaglo Catherine Ogando Alexandra Palmer Alexandra Almonacid Pillar Almonacid |
|||||